Opendata, web and dolomites

TOL2

An effective and safe targeted therapy for treatment of Myasthenia gravis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TOL2 project word cloud

Explore the words cloud of the TOL2 project. It provides you a very rough idea of what is the project "TOL2" about.

arms    first    total    2019    14    swedish    diseases    sales    crisis    chronic    medical    calculated    progress    full    though    wacc    pharma    parts    2021    co    npv    quality    cure    innovative    company    utilize    business    weakness    drug    therapies    patients    payments    257m    patient    global    trials    fda    reducing    breathing    model    everyday    frequently    restricts    legs    royalties    muscles    mission    2029    20    autoimmune    urgent    intrinsic    toleranzia    strategy    moving    induces    treatment    streams    considering    crises    revenue    body    myasthenia    participation    orphan    power    unemployment    remission    designation    investment    symptomatic    pharmaceutical    complete    gravis    immune    disease    causes    skeletal    clinical    neuromuscular    treatments    myasthenic    death    sight    iia    life    surpass    responsible    milestone    treat    mg    look    tolerance    granted    upfront    people    rare    tol2    10    therapy    expensive   

Project "TOL2" data sheet

The following table provides information about the project.

Coordinator
TOLERANZIA AB 

Organization address
address: ERIK DAHLBERGSGATAN 11 A
city: GOTEBORG
postcode: 411 26
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Project website https://www.toleranzia.com/program/sme-instrument-phase-1-project/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-12-01   to  2019-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TOLERANZIA AB SE (GOTEBORG) coordinator 50˙000.00

Map

 Project objective

Myasthenia gravis (MG) is a rare disease affecting 2/10.000 people. Although being a rare disease, MG is the most common chronic autoimmune neuromuscular disease that causes weakness in the skeletal muscles, which are responsible for breathing and moving parts of the body, including the arms and legs. MG restricts patients from having a full participation in everyday activities, frequently leading to unemployment and reducing their quality of life. Many patients may eventually experience a myasthenic crisis, the treatment of which is very expensive. Such crises can lead to the death of the patient. There is currently no cure for MG and neither is there any cure in sight. Even though there are over 30 MG-related clinical trials currently in progress, most of them are only symptomatic treatments.

Considering this urgent medical need, we are developing TOL2, an innovative therapy with potential to cure MG (not only symptomatic treatment). This will be the first therapy for MG that induces long-term remission. TOL2 is based on a tolerance-technology with potential to be developed for treatment of other autoimmune diseases. TOL2 has been granted Orphan Drug Designation by the US FDA.

Toleranzia is a Swedish pharmaceutical research and development company. Our therapies utilize the immune system’s own intrinsic power to treat autoimmune diseases. Our mission is to develop innovative therapies that will cure autoimmune diseases.

Our business strategy for TOL2 is to complete clinical phase IIa, and then to look for an agreement with a global pharma partner, who can or co-develop the therapy. Under this business model, revenue streams are obtained through upfront payments, milestone payments and royalties on product sales.

Considering total project cost of €5,6 m during years 2019-2021, upfront payments above €14 m and 20% royalties over sales, the NPV of the investment calculated (WACC 10%) will surpass €257m by 2029.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TOL2" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TOL2" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

COPI (2020)

Carbon Offset Plug-in

Read More  

HUD (2018)

COMMERCIALIZING THE FIRST HEAD-UP-DISPLAY FOR OFF-HIGHWAY VEHICLES

Read More  

C-Air (2018)

An innovative, reliable, lifesaving industrial air purification system that contains, cleans, and purifies air contaminated by toxic gases.

Read More